Company Overview and News
SEATTLE, WA--(Marketwired - January 10, 2018) - Corum Group, the leading M&A advisory firm for software and related technology companies, today announced that its client, Lending Manager, has been acquired by Loyalty Express.
SEATTLE, WA--(Marketwired - January 09, 2018) - Corum Group, the leading M&A advisory firm for software and related technology companies, today announced that its client, Infian, has sold its assets to Quantitative Medical Systems. The combined company will be the leading dialysis software provider in the United States.
SALT LAKE CITY, UT--(Marketwired - May 22, 2017) - Corum Group, the leading global software M&A advisory firm, announced today that its client Hospicesoft, a supplier of cloud-based software for hospices, was acquired by Optima Healthcare Solutions, a leading provider of cloud-based software for post-acute care providers. Optima is a portfolio company of Alpine Investors V, LP and affiliated funds managed by Alpine Investors.
NEW YORK, NY--(Marketwired - Jan 31, 2017) - Israel-based Cannabi-Tech Ltd. (CBT), a pioneering provider of lab-grade medical cannabis quality control testing systems, today announced that the company has closed a seed investment round of $1 million, and appointed two new directors to its board. The round will support the North American launch of Cannabi-Tech's fully-integrated testing platform for medical cannabis labs and dispensaries.
SEATTLE, WA--(Marketwired - January 12, 2016) - Corum Group, the leading M&A advisory firm for software and related technology companies, will present its annual overview of the current technology mergers and acquisitions environment on Thursday, January 14, 2016, during an hour-long webcast. "Forecast 2016: Global Tech M&A Report" will include...
2018-04-25 - Asif
Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...
2018-04-25 - Asif
Overview Amazon.com opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...
2018-04-23 - Asif
Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...